Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 3.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 260,789 shares of the biopharmaceutical company’s stock after selling 10,368 shares during the quarter. Assenagon Asset Management S.A. owned 0.47% of Marinus Pharmaceuticals worth $305,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Marinus Pharmaceuticals in the 2nd quarter worth $34,000. Jacobs Levy Equity Management Inc. purchased a new position in Marinus Pharmaceuticals in the 1st quarter worth about $384,000. Trexquant Investment LP acquired a new stake in Marinus Pharmaceuticals during the 4th quarter worth about $553,000. Hussman Strategic Advisors Inc. purchased a new stake in Marinus Pharmaceuticals during the first quarter valued at about $664,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Marinus Pharmaceuticals in the fourth quarter worth approximately $1,146,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Price Performance

MRNS opened at $1.30 on Friday. The company has a current ratio of 3.07, a quick ratio of 2.93 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals, Inc. has a 1 year low of $1.05 and a 1 year high of $11.26. The stock has a fifty day moving average price of $1.31 and a 200 day moving average price of $4.00. The stock has a market cap of $71.41 million, a price-to-earnings ratio of -0.49 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The firm had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. During the same period in the previous year, the firm posted ($0.61) EPS. Analysts forecast that Marinus Pharmaceuticals, Inc. will post -1.87 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MRNS has been the subject of several research analyst reports. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. Truist Financial reaffirmed a “buy” rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Finally, StockNews.com downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $12.75.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.